Clinical trial registry record

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 9, 2016.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01796964
Last registry update
February 9, 2016
Status
Completed
Phase
Phase 2
Sponsor
Alcon Research
Enrollment
173
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
173
Population
ALL · 50 Years
Duration
2013-03-01 to 2014-08-01
Intervention
ESBA1008 solution; Aflibercept
Comparator
EYLEA
Outcomes measured
Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12 — Baseline (Day 0), Week 12; BCVA Change From Baseline (No. of Letters) to Week 16 — Baseline (Day 0), Week 16; BCVA Change From Baseline (No. of Letters) by Visit — Baseline (Day 0), Week 4, Week 8, Week 20, Week 24, Week 28, Week…; Average BCVA Change From Baseline (No. of Letters) Over the Periods of Week 4 to Week 16, Week 4 to Week 24, Week 4 to…; Average BCVA Change From Week 12 (No. of Letters) Over the Periods of Week 16 to Week 24, Week 16 Week 40, and Week 16…; One-Month BCVA Changes (No. of Letters) Following No Treatment for 1-Month — Week 12, Week 16, Week 20, Week 24, Week 2…; One-Month BCVA Changes (No. of Letters) Following Treatment by Visit — Week 16, Week 20, Week 24, Week 28, Week 32, Wee…; Two-Months BCVA Changes (No. of Letters) Following No Treatment for 1 Month in ESBA Treatment Group — Week 36, Week 44,…; Central Subfield Thickness (CSFT) Change From Baseline by Visit — Baseline (Day 0), Week 4, Week 8, Week 12, Week 16, W…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON